Loading...
Market
Will Gilead and LEO Pharma announce positive Phase II results for STAT6 drug in 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases from Gilead Sciences or LEO Pharma, and clinical trial registries
Story
Gilead Sciences Partners with LEO Pharma, Paying $250M for Oral Drug Targeting STAT6 in Inflammatory Diseases
Jan 11, 2025, 05:03 PM
Gilead Sciences has entered into a strategic partnership with LEO Pharma, focusing on the development of an oral drug targeting STAT6, which has potential applications in treating various inflammatory diseases. As part of the agreement, Gilead will pay LEO Pharma $250 million upfront to license the drug. This collaboration aims to accelerate the development of the STAT6 program, which is expected to address unmet medical needs in the field of inflammatory diseases.
View original story
Similar markets
Yes • 50%
No • 50%
Positive efficacy, but safety concerns • 25%
Negative efficacy and safety concerns • 25%
Negative efficacy, but good safety • 25%
Positive efficacy and safety results • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Drug C • 25%
Drug A • 25%
Drug B • 25%
None • 25%
